10-Q: Cardio Diagnostics Holdings Reports First Quarter 2024 Results, Revenue Growth and Increased Operating Expenses

Cardio Diagnostics Holdings, Inc. reported a net loss of $4.16 million for the first quarter of 2024, with revenue of $15,928 and increased operating expenses.

Summary

• Cardio Diagnostics Holdings, Inc. reported a net loss of $4,163,584 for the quarter ended March 31, 2024, compared to a net loss of $1,032,618 for the same period in 2023.
• The company generated revenue of $15,928 in the first quarter of 2024, a significant increase from no revenue in the same period of 2023.
• Operating expenses totaled $4,173,976, which is a substantial increase from $1,703,129 in the first quarter of 2023.
• General and administrative expenses saw a large increase, rising to $4,123,941 from $1,562,128 year-over-year, primarily due to stock compensation, increased personnel, and rent.
• Research and development expenses decreased to $10,840 from $86,665 year-over-year, due to fewer laboratory runs.
• The company's cash balance increased to $1,563,139 as of March 31, 2024, from $1,283,523 at the end of 2023.
• The company issued 1,048,876 shares of common stock for cash, raising $1,877,857.
• The company has an accumulated deficit of $18,531,964 as of March 31, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments like revenue generation and new partnerships, but the significant increase in net loss, high operating expenses, going concern warning, and potential legal issues create a negative sentiment overall. The company's reliance on further capital raises and the regulatory uncertainty surrounding LDTs also contribute to the low score.

Positives

• The company generated its first revenue of $15,928 in Q1 2024.
• The company's cash balance increased by $279,616 during the quarter.
• The company successfully raised $1,877,857 through the issuance of common stock.
• The company's CPT PLA codes became effective, which may improve reimbursement.
• The company secured a nationwide telehealth agreement with Navierre, expanding its reach.

Negatives

• The company's net loss increased significantly to $4.16 million in Q1 2024.
• General and administrative expenses increased substantially to $4.12 million.
• The company has an accumulated deficit of $18,531,964.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund operations.

Risks

• The company's ability to continue as a going concern is dependent on obtaining necessary equity financing and generating revenues.
• Additional issuances of equity or convertible debt securities will result in dilution to current stockholders.
• The company may not be able to obtain additional financing on acceptable terms, or at all.
• The company faces potential legal claims from Boustead Securities, Benchmark Company, and Northland Securities.
• The company is subject to new FDA regulations for laboratory developed tests (LDTs), which may increase costs and regulatory burdens.
• The company's stock price has been volatile and may not meet Nasdaq's minimum bid price requirements.

Future Outlook

The company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. The company anticipates additional increases in operating expenses and capital expenditures relating to developmental and marketing expenses. The company intends to finance these expenses with further issuances of securities and debt issuances. The company expects that sales and partnership cycles will continue to be long.

Management Comments

• The company aspires to give every American adult insight into their unique risk for various cardiovascular diseases.
• Cardio aims to become one of the leading medical technology companies for enabling improved prevention, early detection and treatment of cardiovascular disease.
• Cardio is transforming the approach to cardiovascular disease from reactive to proactive and hope to accelerate the adoption of Precision Medicine for all.
• The company believes that incorporating Cardio's solutions into routine practice in primary care and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035.
• The company believes that it is the first company to develop and commercialize epigenetics-based clinical tests for cardiovascular disease that have clear value propositions for multiple stakeholders.

Industry Context

The company operates in the medical technology sector, focusing on cardiovascular disease diagnostics using AI-driven genetic and epigenetic testing. The company is attempting to shift the approach to cardiovascular disease from reactive to proactive, aligning with the broader trend of personalized medicine and early disease detection. The company's focus on epigenetics is a relatively new area in diagnostics, which could provide a competitive advantage if proven effective and adopted by clinicians and payers.

Comparison to Industry Standards

• The company's revenue of $15,928 is very low compared to established diagnostic companies, which often report millions or billions in quarterly revenue.
• The company's net loss of $4.16 million is significant for a company of its size and stage, indicating a high burn rate and a need for substantial capital.
• The company's reliance on equity financing is common for early-stage biotech companies, but the company's current stock price and volatility make this a risky strategy.
• The company's focus on epigenetics is a differentiator, but it also means that the company is operating in a less established market with more regulatory uncertainty.
• The company's CPT PLA codes are a positive development, but reimbursement rates and adoption by payers will be critical for future revenue growth.
• The company's telehealth agreement with Navierre is a positive step, but the company will need to demonstrate that it can generate significant revenue through this channel.
• The company's financial results are not comparable to established companies like Exact Sciences (EXAS) or Myriad Genetics (MYGN), which have established revenue streams and more mature product portfolios. The company is more comparable to early-stage biotech companies that are still in the development and commercialization phase.

Legal Proceedings

• The company is evaluating a claim from The Benchmark Company, LLC regarding a right of first refusal.
• The company is disputing a claim from Boustead Securities, LLC regarding success fees.
• The company is disputing a claim from Northland Securities, Inc. regarding a fee for the Yorkville financing.
• The company is facing a potential mootness fee claim from a plaintiffs securities law firm.

Stakeholder Impact

• Shareholders face potential dilution from further equity issuances and the risk of a reverse stock split.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers may be affected by the company's ability to continue operations and provide services.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.
• The company's ability to continue as a going concern is dependent on its ability to obtain necessary equity financing and ultimately from generating revenues to continue operations.

Next Steps

• The company plans to develop additional products, including clinical tests for stroke, congestive heart failure, and diabetes.
• The company intends to expand its clinical and health economics evidence portfolio.
• The company will leverage its newly-awarded CPT PLA codes.
• The company plans to expand the adoption of its products across key channels, including health systems and self-insured employers.
• The company will scale its internal operations capabilities with a focus on improving efficiency and reducing its cost of goods sold.
• The company will pursue potential strategic partnerships and acquisitions of synergistic companies.

Key Dates

Keywords

Cardiovascular Disease, Epigenetics, Genetics, Precision Medicine, Laboratory Developed Tests, LDTs, AI, Artificial Intelligence, Telehealth, CPT PLA Codes, Stock Issuance, Financial Results, Going Concern